Signaturefd, LLC Akero Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.21 Billion
Q4 2024

A detailed history of Signaturefd, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 1,578 shares of AKRO stock, worth $74,907. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,578

Previous 1,578 -0.0%

Holding current value

$74,907

Previous $45,000 4.44%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$21.45 - $29.34 $1,244 - $1,701	58 Added 3.82%	1,578 $45,000
Q2 2024 Jul 29, 2024	BUY	$18.31 - $24.62 $366 - $492	20 Added 1.33%	1,520 $35,000
Q1 2024 May 03, 2024	BUY	$17.76 - $31.18 $301 - $530	17 Added 1.15%	1,500 $37,000
Q4 2023 Jan 31, 2024	SELL	$11.38 - $50.33 $5,769 - $25,517	-507 Reduced 25.48%	1,483 $34,000
Q3 2023 Nov 03, 2023	SELL	$41.19 - $52.25 $370 - $470	-9 Reduced 0.45%	1,990 $100,000
Q2 2023 Aug 01, 2023	SELL	$36.89 - $56.88 $1,143 - $1,763	-31 Reduced 1.53%	1,999 $93,000
Q1 2023 Apr 28, 2023	SELL	$37.27 - $50.24 $5,292 - $7,134	-142 Reduced 6.54%	2,030 $77,000
Q4 2022 Jan 27, 2023	BUY	$33.44 - $54.8 $4,046 - $6,630	121 Added 5.9%	2,172 $119,000
Q3 2022 Nov 08, 2022	BUY	$10.15 - $34.05 $13,550 - $45,456	1,335 Added 186.45%	2,051 $70,000
Q2 2022 Aug 10, 2022	BUY	$8.0 - $15.01 $4,760 - $8,930	595 Added 491.74%	716 $7,000
Q1 2022 May 02, 2022	BUY	$12.97 - $22.26 $1,569 - $2,693	121 New	121 $2,000
Q4 2021 Jan 25, 2022	SELL	$19.87 - $26.24 $953 - $1,259	-48 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$18.65 - $25.46 $895 - $1,222	48 New	48 $1,000

Others Institutions Holding AKRO

# of Institutions

210

Shares Held

74.3M

Call Options Held

321K

Put Options Held

558K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.2B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account